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Background:  Community-acquired  pneumonia  (CAP)  is one  of  the  most  common  acute  infections  associ-
ated  with  a substantial  clinical  and economic  burden.  There  have  been  few  studies  assessing  incidence
rate, duration  of hospitalization,  and  costs  of  hospitalized  CAP  by  age  and  care-setting.
Methods:  A  retrospective  study  was  conducted  using  a nationwide  Dutch  database  containing  healthcare
claims  data  of  16.7  million  inhabitants.  Patients  with  at least  one  claim  with  a discharge  diagnosis  of  CAP
between  January  2008  and  December  2011  were  selected.  The  main  outcome  measures  considered  were
the  incidence  rate,  duration  of  hospitalization,  and  the  direct costs  of  hospitalized  CAP  stratiﬁed  by age
and  care-setting.
Results:  In total,  195,372  CAP  cases  were  included  in  the  analysis  resulting  in  an  average  incidence  of  295
per  100,000  population  per  year.  Sixty-three  percent  (123,357)  of the  included  patients  were  hospitalized
for 1  or  more  nights,  of which  5.9%  (n = 7241)  spent  at least  one  night  in the  Intensive  Care  Unit (ICU).
Overall,  these  123,357  patients  spent  824,985  days  in  the  hospital  of  which  48,324  were  spent  on  the
ICU.  The  mean  duration  of hospitalization  of  ICU  patients  and  general  ward  patients  was 15.2  days  and
6.2  days,  respectively.  The  total  costs  related  to all  195,372  CAP  episodes  during  these  4 years  were  D  711
million,  with  the  majority  (76%)  occurring  among  those  aged  50  years  and older.  Median  (and  mean)
costs  were  dependent  on  age  and  type  of care  with  costs  ranging  from  D  344 (D 482)  per  episode  for  0–9
year  olds  treated  in  the  outpatient  hospital  setting  up to  D  10,284  (D  16,374)  per  episode  for  50–64 year
olds  admitted  to the  ICU.
Conclusion:  There  is a large  variation  in terms  of incidence,  disease  burden  and  costs  across  different  age
groups  and  the treatment  setting.  Effective  interventions,  targeted  at older  adults,  to prevent  pneumonia
could  reduce  the  (ﬁnancial)  burden  due  to pneumonia.
ublis©  2015  The  Authors.  P
. Introduction
Community-acquired pneumonia (CAP) is one of the most com-
on  acute infections necessitating hospitalization resulting in a
onsiderable clinical and economic burden [1,2]. In the USA, for
xample, the estimated annual number of CAP episodes in adults is
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el.: +31 (0)10 4064494.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
approximately 5.2 million, with the highest incidence among those
aged 65 years and older (4200 per 100,000 population) [3]. For
most countries, recent data on the (ﬁnancial) burden of pneumo-
nia are lacking. Although a few large database studies have been
published recently focusing on the clinical burden of CAP in (older)
adults [4–7], only one study focused on both the clinical and eco-
nomical burden of CAP [8]. The latter study focused speciﬁcally on
patients aged 50 years and older. To our knowledge, there are no
published studies focusing on the incidence, the duration of hos-
pitalization and the direct cost of hospitalized CAP simultaneously
using a national dataset which covers an entire population. These
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ata are, however, important in order to accurately estimate the
otal burden of disease due to CAP. Furthermore, it was  previously
hown that both the incidence and CAP related costs are impor-
ant drivers of the cost-effectiveness of pneumococcal vaccination
rograms targeting adults [9,10]. Therefore, accurate estimates of
hese parameters are crucial to estimate the cost-effectiveness of
uch programs especially now that the results of the CAPiTA trial
ave shown that the 13-valent polysaccharide conjugate vaccine
PCV13) appeared effective in preventing vaccine-type pneu-
ococcal, bacteremic, and nonbacteremic community-acquired
neumonia and vaccine-type invasive pneumococcal disease in
dults aged 65 years and older [11].
To address this gap in the literature, the present study evalu-
ted the incidence rate, the duration of hospitalizations and the
irect hospitalization cost of CAP stratiﬁed by age and setting of
are using a nationwide database covering the entire population of
he Netherland.
. Methods
.1. Background
.1.1. Current pneumococcal vaccination programs in the
etherlands
In the Netherlands, an infant pneumococcal vaccination pro-
ram was introduced for all infants born after March 31, 2006.
nfant received 3 doses of PCV7 at ages 2–4, and an additional
ooster dose at 11 months (i.e. 3+1). As of 2011, PCV10 replaced
CV7 in the infant pneumococcal vaccination schedule.
For older individuals a 23-valent pneumococcal polysaccharide
accine (PPV23) is available. However, PPV23 is not recommended
or universal use among the elderly [13,14] as there is no convincing
vidence that it prevents non-invasive pneumococcal pneumonia,
here the vast majority of disease burden lies [15,16]. Conse-
uently, the uptake of PPV23 is very low (i.e. less than 1% of those
ged ≥65) [9] compared to, for example, the inﬂuenza vaccination
ptake of approximately 75% [17].
.1.2. Database
In the Netherlands, hospitals are reimbursed based on a com-
ination of diagnosis and treatment: a DBC (Dutch: Diagnose
ehandel Combinatie). This DBC system is accompanied by an
xtensive registration, which is gathered in a national database: the
IS (DBC Information System). This DIS database includes all data
elevant to the hospitals’ reimbursement of their bed occupancy
nd activities. It contains all diagnoses and activities performed by
ll hospitals in the Netherlands (n = 104) covering a population of
6.7 million inhabitants. Furthermore, it contains some basic infor-
ation on patient characteristics (e.g. unique identiﬁers, gender
nd year of birth) and information on the derived care product
hich was reimbursed by the insurance company, like site of care
Intensive Care Unit [ICU] or ward) and length of stay (see also
elow). The database does not contains survival information and
discharge” includes death. For the current study, data from the DIS
atabase were used which were extracted and aggregated by the
utch case-mix ofﬁce DBC-Onderhoud, Utrecht, The Netherlands.
urther, analyses were performed by the authors.
.1.3. Case selection
Patients with at least one medical claim with a ﬁnal discharge
iagnosis of pneumonia between January 2008 and December 2011
ere retrospectively selected. Pneumonia was identiﬁed using
peciﬁc diagnostic codes which were mapped to International
lassiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation
ICD-9-CM) codes (480, 481, 482.xx-483.xx, 484.xx, 485, and
86). Diagnostic codes in the database are classiﬁed according toe 33 (2015) 3193–3199
the medical specialization. The following diagnosis codes were
included to select CAP cases in the analysis: (i) 0313. Internal
medicine: 401. Pneumonia, unspeciﬁed and 402. Interstitial pneu-
monia; (iii) 0316. Pediatrics: 3028. Lower respiratory infections;
(iv) 0322. Pulmonology: 1401. Pneumonia; (v) 0335. Geriatrics:
273. Pneumonia. Only patients with a ﬁnal diagnosis code were
selected. To exclude potential hospital acquired pneumonia (HAP)
episodes, patients were excluded if they had been treated clini-
cally for any other ﬁnal diagnosis than those mentioned above, in
a parallel DBC in the same hospital.
We  differentiated between the following type of care: ICU (hos-
pitalized CAP admitted for at least one night to the ICU), general
ward (hospitalized CAP only admitted to the general ward) and out-
patient hospital setting (ED and outpatient hospital visits without
an overnight stay and therefore not counted as a hospitalization
day). Please note that outpatient CAP in the current study only
include patients treated in the hospital and that cases only treated
by the general practitioner are not collected in the database.
2.1.4. Data and outcome measures
The following data from the DIS database were collected per
case: date of presentation (month, year), age at presentation, type
of care (see above), length of hospital stay separated into those
spent in general ward, ICU, hospital costs, and the specialists’ fees
which are claimed separately.
The outcome measures considered in this study are the inci-
dence rate, duration of hospitalization, and the direct costs of
hospitalized CAP stratiﬁed by age and care-setting. In order to
calculate incidence rates, Dutch population data from Statistics
Netherlands were extracted from the electronic databank Statline
[12].
2.2. Analyses
All above mentioned study variables were analyzed using
Microsoft Excel (Microsoft, Redmond, WA,  USA). Descriptive statis-
tics (mean, standard deviation (SD), median, and inter quartile
range (IQR)) were calculated. Depending on the outcome measure
(i.e. sample size) the study population was either divided into (i):
age bands of 5 years with the exception of those aged less than 5
years which were divided into 1 year age bands and those aged 85
years and over who were aggregated into a single group, (ii) or into
the following age groups 0–9, 10–17, 18–49, 50–64, 65–74, 75–84
and 85 years and older if the sample size (<50 cases per age class)
was not sufﬁcient to provide ﬁner age grouping.
3. Results
3.1. Incidence
A total of 195,372 CAP episodes were included in the analysis
between January 2008 and December 2011. The overall number
of CAP episodes were stable throughout the ﬁrst 3 years (47,119;
48,522; 46,994 for 2008, 2009, 2010 respectively) while a small
increase was  observed in 2011 (n = 52,737). The mean annual num-
ber of CAP episodes throughout the entire study period was 48,843
resulting in an average incidence of 295 per 100,000 inhabitants
per year. Across treatment settings, the highest incidence rate was
found for treatment episodes in the general ward (176 per 100,000
inhabitants per year), followed by those treated in the outpatient
setting (109 per 100,000 inhabitants per year) and in the ICU (11
per 100,000 inhabitants per year). Approximately 45% and 64% of
all CAP episodes occurred in individuals aged 65 years (incidence
of 881 per 100,000 inhabitants per year) and 50 years and older
(incidence of 535 per 100,000 inhabitants per year), respectively.
Within the more severe episodes (i.e. excluding outpatient cases)
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ospital setting (black bars with white dots) are displayed on the left axis while the
isplayed on the right axis with a different scale.
hese percentages increased to 54% and 71% for 65 and 50 years and
lder individuals, respectively.
Fig. 1 shows the age- and care-setting speciﬁc incidence rate
f hospitalized CAP. The incidence follows a U-shaped curve with
he highest incidence among those aged less than 5 years of age
nd those aged 60 years and older. In particular, from age 45 to 50
ears onwards, the incidence rate of overall CAP starts increases
xponentially with approximately 36% per 5-year age group. In
ddition, with increasing age, the proportion of patients treated
n the inpatient setting increased. For example, in 80–84 years old
0% of episodes were treated in the inpatients setting compared
o 56% for those aged 50–54 years. Although the overall inpatient
roportion increases with age, the proportion and the incidence of
atients admitted to the ICU decreased after the age of 85.
.2. Length of stay in the hospital
In total 123,357 (63%) of all included episodes were hospitalized
or 1 or more nights of which 5.9% (n = 7241) spent at least one
ight on the ICU. Overall, these 123,673 patients spent 824,985 days
n the hospital of which 48,324 were spent on the ICU, resulting
n a overall mean length of stay of 6.7 days. The mean length of
tay in the hospital of patients treated in the ICU (15.2 days) was
ubstantially longer than those treated in the general ward (6.2
ays). ICU patients spent 44% of hospitalized time on the ICU (i.e.
.7 days).
In general, the mean length of stay of patients treated in the gen-
ral ward increased with age from around 3.6 days in the youngest
hildren up to 7.7 days in adults ≥85 years (Table 1). In contrast to
hose patients only treated in the general ward, the mean length
f stay in the hospital in patients treated in the ICU decreased after
he age of 75 years (see Table 1 and Fig. 2).
.3. Costs of hospitalization
The 195,372 CAP episodes resulted in a total ﬁnancial burden
f D 711 million, corresponding to a mean annual cost of D 178
illion. The general ward cost contributed with 77.5% (D 551 M)
he most to the overall costs, followed by the ICU costs with 15.4%
nd the outpatient hospital costs (7.1%). The median costs per CAP
pisode (partially) treated in the ICU (D 6000–D 10,000) were 2–3ted in the general ward (gray bars with black diagonal lines) and in the outpatient
ence rate of CAP treated (partially) in the ICU (red bars with vertical black lines) is
times higher compared to those episodes treated only in the gen-
eral ward (D 2000–D 50,000) The median costs for an outpatient
hospital visit was substantially lower, varying from D 300 to D 800
per episode.
Fig. 3 shows the total costs of CAP by age group for the entire
study period (2008–2011) split by age and care-setting. The major-
ity of the costs are generated in the elderly. In particular 76% of
the total CAP costs are attributable to those aged 50 years and
older. The median costs per CAP case treated in the general ward
was very similar between all adults age groups (with a mean and
median around D 5000) and between those aged 18 years or less
(mean and median of around D 2750 and D 2300, respectively). The
costs of patients treated in the ICU were more similar across all age
groups, although here, the mean costs in the youngest and oldest
age groups were lower compared to the other age groups (please
note that the numbers in the youngest age groups are relatively
small, see also Table 1). Finally, the mean outpatient hospitaliza-
tion costs were the only costs that increased with age, from a mean
cost of D 482 (median D 344) in 0–9 year olds up to around D 757
(median D 361) in the oldest age groups.
4. Discussion
This is, to our knowledge, the ﬁrst study using a healthcare claim
database covering the entire population to estimate the age and the
type of care speciﬁc incidence, duration of hospitalization and the
direct hospitalization costs CAP. We  found that the average annual
incidence of hospitalized CAP is 295 per 100,000 inhabitants per
year leading to approximately 49,000 hospitalizations and a ﬁnan-
cial burden of D 178 million annually in the Netherlands. This D 178
million corresponds to 51% of the annual budget spent in hospitals
on the treatment and prevention of infectious diseases [18].
We also found that there is a large variation in terms of inci-
dence, disease burden and costs across different age groups and
the treatment setting. In particular, those aged 50 years and older
are disproportionately affected by hospitalized CAP with the major-
ity of the CAP episode (64%) and costs (76%) occurring among this
group while representing only 35% of the Dutch population. Indi-
viduals under the age of 5 years are affected in a similar way (13%
episodes, and 6% of the population) although the total treatment
costs (5% of the total costs) in this age groups is relatively low as
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Table 1
Number of episodes, annual incidence, costs and duration of hospitalization.
Age group Number of
episodes
Incidence per
100,000
Total costs
during study
period
(2008–2011)
Mean (SD) cost
per episode
Median (IQR)
cost per
episode
Total length of
hospital stay
during study
period
(2008–2011)
Mean (SD)
length of
hospital stay
per episode
Median (IQR)
length of
hospital stay
per episode
Overall CAP (all CAP cases combined)
0–9 34,606 447 D 52,188,440 D 1508 (D 1389) D 2190 (D 321: D 2279) 60,729 1.75 (3.27) 0  (0: 2)
10–17  4356 69 D 6,886,475 D 1581 (D 4668) D 692 (D 321: D 2279) 8093 1.86 (4.74) 0  (0: 2)
18–49 32,039 111 D 108,692,358 D 3393 (D 3932) D 4854 (D 777: D 5145) 88,828 2.77 (5.13) 1 (0: 4)
50–64  36,131 273 D 142,657,253 D 3948 (D 5693) D 4887 (D 790: D 5180) 145,690 4.03 (7.15) 1 (0: 6)
65–74 31,671 577 D 137,912,703 D 4355 (D 5847) D 4935 (D 914: D 5220) 164,784 5.2 (7.94) 2 (0: 8)
75–84  36,535 1084 D 170,538,683 D 4668 (D 5114) D 5034 (D 4819: D 5251) 226,679 6.2 (7.86) 4 (1: 9)
85  and over 20,034 1724 D 91,785,200 D 4581 (D 2580) D 5034 (D 4856: D 5251) 130,182 6.5 (7.41) 5 (1: 9)
CAP  treated in the general ward
0–9 16,809 217 D 42,835,162 D 2548 (D 679) D 2279 (D 2206: D 2528) 60,128 3.58 (3.86) 3 (1: 4)
10–17  1743 27 D 5,068,043 D 2908 (D 1040) D 2279 (D 2236: D 3275) 7766 4.46 (6.34) 3 (1: 5)
18–49  16,085 56 D 82,686,913 D 5141 (D 625) D 5102 (D 4935: D 5274) 74,454 4.63 (4.42) 4 (1: 6)
50–64  19,290 146 D 99,391,781 D 5153 (D 594) D 5081 (D 4887: D 5253) 115,235 5.97 (5.84) 5 (2: 8)
65–74 19,553  356 D 100,660,679 D 5148 (D 567) D 5069 (D 4887: D 5253) 135,246 6.92 (6.7) 6 (2: 9)
75–84  26,349 782 D 135,639,913 D 5148 (D 570) D 5069 (D 4887: D 5253) 197,585 7.5 (6.98) 6 (2: 10)
85  and over 16,287 1401 D 84,311,610 D 5177 (D 626) D 5081 (D 4935: D 5253) 124,745 7.66 (7.27) 6 (2: 11)
CAP  treated (partially) in the ICU
0–9 70 1 D 809,681 D 11,567 (D 11,992) D 6429 (D 4444: D 14,328) 601 8.59 (9.27) 4 (2: 13)
10–17  33 1 D 523,380 D 15,860 (D 49,851) D 5823 (D 3738: D 8181) 327 9.91 (12.46) 6 (2: 14)
18–49  1071 4 D 15,239,015 D 14,229 (D 13,771) D 9460 (D 7079: D 16,168) 14,374 13.42 (14.94) 9 (4: 16)
50–64 1900  14 D 31,111,478 D 16,374 (D 19,042) D 10,284 (D 7424: D 18,077) 30,455 16.03 (17.75) 11 (5: 20)
65–74  1793 33 D 28,696,800 D 16,005 (D 19,568) D 10,000 (D 7390: D 16,736) 29,538 16.47 (17.59) 12 (6: 21)
75–84  1932 57 D 28,097,645 D 14,543 (D 17,959) D 9353 (D 7047: D 14,886) 29,094 15.06 (15.38) 11 (5: 20)
85  and over 442 38 D 4,972,460 D 11,250 (D 10,547) D 8171 (D 6653: D 11,439) 5437 12.3 (11.85) 9 (4: 17)
CAP  treated in the outpatient hospital setting
0–9 17,727 229 D 8,543,598 D 482 (D 540) D 344 (D 224: D 463) N/A N/A N/A
10–17  2580 41 D 1,295,052 D 502 (D 520) D 374 (D 224: D 505) N/A N/A N/A
18–49  14,883 52 D 10,766,430 D 723 (D 590) D 771 (D 260: D 805) N/A N/A N/A
50–64  14,941 113 D 12,153,995 D 813 (D 704) D 788 (D 531: D 911) N/A N/A N/A
65–74  10,325 188 D 8,555,224 D 829 (D 777) D 788 (D 361: D 871) N/A N/A N/A
75–84  8254 245 D 6,801,125 D 824 (D 961) D 767 (D 260: D 805) N/A N/A N/A
85  and over 3305 284 D 2,501,131 D 757 (D 1116) D 361 (D 239: D 789) N/A N/A N/A
N/A: not applicable, population size per age group: 0–9 years: 7.7 million, 10–17 years: 6.4 million;18–49 years: 28.8 million, 50–64 years: 13.2 million, 65–74 years:5.5 million, 75–84 years: 3.4 million, 85 years and over:1.2
million.
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eneral  ward while the red bars (with vertical black lines) show the mean duration
lmost half of the episodes are treated in the outpatient (hospital)
etting. Finally, the general ward and ICU hospitalizations con-
ributed with 92.9% to the vast majority of the total hospitalization
osts.
.1. Comparisons to other database studies
In Germany, a neighboring country, the incidence of hospital-
zed CAP cases in those aged ≥18 years was estimated to be very
imilar to our study (296 per 100,000 inhabitants in 2006 as com-
ared to 301 in our study) [4]. The incidence was  estimated higher
n a recent Portuguese study for the same age group, with 361 per
00,000 population [6]. Other recent studies found annual inci-
ences of hospitalized CAPs of 366, 472, 518, 627 and 832 per
00,000 inhabitants for those aged ≥50 years in Czech republic,
lovakia, Poland, Spain and Hungary, respectively [5,8]. If we look
t the same age-group in our study we observe an incidence of 535
er 100,000 population which is well in between the estimates of
hese other European countries. Similar to our study, all studies
ho reported age-speciﬁc incidences showed a steep increase in
he incidence of hospitalized CAP with age in adults [4,7,8,19,20].
lthough our observed incidences are similar to those described
arlier one should take into account factors which can impact the
ig. 3. Total costs of community-acquired pneumonia (CAP) by age groups and type of c
epresent the CAP costs due to episodes hospitalized in the general ward, the red bars wi
he  ICU, and black bars with white dots lines represent CAP costs related to outpatient ho bars (with diagonal black) show the mean duration of hospitalization spend in the
 in the ICU.
country speciﬁc incidence of pneumonia, like immunization pro-
grams.
The median duration of hospitalization for different age groups
found in our study (3–6 days for those admitted to the general
ward) is similar to those found previous in England (3–9 days) [7]
while the mean length of stay in the hospital found for Spain was  up
to 100% longer than we found in our study (13 days vs 7.6 days in our
study for those aged 50 years and older) [5]. A possible explanation
for the difference between Spain and the UK and the Netherlands
might be the availability of continuing care outside the hospital
environment.
Comparing costs per episode between different countries is dif-
ﬁcult as resource prices and diagnostics and treatment standards
may  vary. Our mean costs of (≈D 5000) for hospitalized adults on
the general ward are very similar to a recent smaller prospective
(≈D 4000) and retrospective (≈D 4900) studies performed in the
Netherlands [21,22]. Similar to our study, a study performed in
the USA also showed that while the mean length of hospital stay
increased with age, the costs did not increase proportionally to the
length of stay in the hospital [23]. In our study this can be explained
by the fact that hospitals are reimbursed based on prices for a com-
bination of diagnosis and treatment which may  include a wide
range of hospitalized days. Only when the maximum number of
days within this range is exceeded, additional costs can be charged.
are during the study period (2008–2011). The gray bars with black diagonal lines
th vertical black lines represent the CAP costs due to episodes treated (partially) in
spitalizations.
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.2. Strength and weaknesses of the study
In comparison with previous studies our results might be more
eneralizable as we cover an entire population rather than spe-
iﬁc groups such as elderly, or individuals with commercial medical
eneﬁts or medical coverage. Obviously, our study suffers from the
imitations of using a healthcare claim database. The ICD codes,
hich were mapped to diagnostic codes, are similar to those used
y previous studies. However, on top of these diagnostics codes we
ere able to apply additional criteria to exclude HAPs. The approach
sed to deﬁne a HAP can, however, only be considered as a proxy to
etermine a true HAP since speciﬁc data required to identify HAP
ere not available in the database. A previous Dutch study showed
hat the overall sensitivity of the ICD9 coding for detecting con-
rmed hospitalized CAP was 72% for the principal code [24], which
s similar to a recent study in the USA (62%) [20,25]. On the other
and, also some cases of CAP might have been missed (due to lack
f speciﬁcity of the coding system), especially in the case of a CAP
pisode complicated by respiratory failure, shock or sepsis when
he latter was encoded as the primary code of hospitalization (i.e.
nder-reporting). Unfortunately, mortality data were not collected
ithin the used database. Previous studies have shown huge vari-
ty in case-fatality rates of 0 up to 47%, but all showed an increasing
ortality with age [4,7,8]. The high mortality rates in the oldest age
roups can explain the lower duration of hospitalization of those
dmitted in the ICU aged ≥75 years and older compared to those
ge between 50 and 75 years.
It is known that certain chronic illnesses such as diabetes (preva-
ence in the Netherlands 4.8%), chronic heart and lung disease
prevalence of 5.8% and 7.5% respectively) [26] are associated
ith an increased risk for pneumonia [3,23,27]. Unfortunately,
ata regarding comorbidities were not available in the database
o we were not able to calculate risk group speciﬁc incidences.
imilarly, the database did also not contain information on the
icrobial etiology. Streptococcus pneumoniae is generally accepted
o be the most common cause of CAP [28]. A recent Dutch study
mong 505 patients hospitalized with community-acquired pneu-
onia showed that in those cases in which a pathogen could be
etected (n = 295) S. pneumoniae was causative pathogen in 42% of
he cases [22]. Furthermore, data from the CAPiTA trial showed that
3% of the ﬁrst episodes of community-acquired pneumonia were
pisodes caused by the 13 vaccine serotypes included in PCV13 [11].
We  did not observe an increase in CAP incidence during the
009–2011 ﬂu pandemic. The main reason might be that we did
ot include inﬂuenza in our analysis but solely focused on pneumo-
ia. Furthermore, the increase awareness during the ﬂu pandemic
ight have limited the number of cases with bacterial superinfec-
ion.
.3. Implications and future research
We  show that CAP represents a substantial disease and eco-
omic burden, especially in the elderly. In the next decades both
he incidence and costs related to CAP are expected to raise, as the
aby boomers are approaching senescence and due to a continues
ncrease in the general life expectancy. Although, CAP guidelines
rom major medical societies already highlight the need for
revention efforts [29,30], the CAP-induced health and economic
urden suggests that there is a need for additional preventive
easures. However, before a preventive program (e.g. vaccina-
ion) would be implemented, among others, the cost-effectiveness
eeds to be evaluated. The current research, where the costs of
ospitalized CAP has been determined, is a ﬁrst step for such an
valuation. In order to obtain risk group speciﬁc costs estimates,
o accurately estimate the cost-effectiveness, speciﬁc data with
egard to etiology, quality-of-life losses, and costs of continuing
[e 33 (2015) 3193–3199
care outside the hospital environment due to pneumonia and
are required [31]. Such information would not only be useful
when determining the overall cost-effectiveness of a vaccination
program in elderly, but could help to deﬁne speciﬁc target groups.
5. Conclusion
There is a large variation in terms of incidence, disease burden
and costs across different age groups and the treatment setting.
Effective interventions, targeted at speciﬁc age-groups, to prevent
pneumonia could reduce the disease and ﬁnancial burden due to
pneumonia.
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